Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Peter J. Wierstra"'
Autor:
Iris M. Hagemans, Peter J. Wierstra, Kas Steuten, Janneke D. M. Molkenboer-Kuenen, Duco van Dalen, Martin ter Beest, Johan M. S. van der Schoot, Olga Ilina, Martin Gotthardt, Carl G. Figdor, Ferenc A. Scheeren, Sandra Heskamp, Martijn Verdoes
Publikováno v:
Journal of Nanobiotechnology, Vol 20, Iss 1, Pp 1-15 (2022)
Abstract Background While immune checkpoint inhibitors such as anti-PD-L1 antibodies have revolutionized cancer treatment, only subgroups of patients show durable responses. Insight in the relation between clinical response, PD-L1 expression and intr
Externí odkaz:
https://doaj.org/article/bce30ec5271e44dfb6d7dc4a81599ac1
Autor:
Iris M. Hagemans, Peter J. Wierstra, Kas Steuten, Janneke D. M. Molkenboer-Kuenen, Duco van Dalen, Martin ter Beest, Johan M. S. van der Schoot, Olga Ilina, Martin Gotthardt, Carl G. Figdor, Ferenc A. Scheeren, Sandra Heskamp, Martijn Verdoes
Publikováno v:
Journal of Nanobiotechnology, Vol 20, Iss 1, Pp 1-3 (2022)
Externí odkaz:
https://doaj.org/article/145df4837af84e51a6fd6145a71f73f9
Autor:
Iris Koopmans, Djoke Hendriks, Douwe F. Samplonius, Robert J. van Ginkel, Sandra Heskamp, Peter J. Wierstra, Edwin Bremer, Wijnand Helfrich
Publikováno v:
OncoImmunology, Vol 7, Iss 8 (2018)
PD-L1-blocking antibodies produce significant clinical benefit in selected cancer patients by reactivating functionally-impaired antigen-experienced anticancer T cells. However, the efficacy of current PD-L1-blocking antibodies is potentially reduced
Externí odkaz:
https://doaj.org/article/e22cb3f785134639905fdb9be9107749
Autor:
Willemijn A. Hobo, Erik H.J.G. Aarntzen, Harry Dolstra, Otto C. Boerman, Johan Bussink, Daniel Olive, Jeannette Cany, Soley Thordardottir, Gerwin W. Sandker, Janneke D.M. Molkenboer-Kuenen, Peter J. Wierstra, Sandra Heskamp
Antibodies that block the interaction between programmed death ligand 1 (PD-L1) and PD-1 have shown impressive responses in subgroups of patients with cancer. PD-L1 expression in tumors seems to be a prerequisite for treatment response. However, PD-L
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dcf012cc714ed1a4486ab1a6ea08d03a
https://doi.org/10.1158/2326-6066.c.6548185.v1
https://doi.org/10.1158/2326-6066.c.6548185.v1
Autor:
Willemijn A. Hobo, Erik H.J.G. Aarntzen, Harry Dolstra, Otto C. Boerman, Johan Bussink, Daniel Olive, Jeannette Cany, Soley Thordardottir, Gerwin W. Sandker, Janneke D.M. Molkenboer-Kuenen, Peter J. Wierstra, Sandra Heskamp
Supplemental Figure 3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29084ab7ab3d6eca96b2a2699dff722c
https://doi.org/10.1158/2326-6066.22536622
https://doi.org/10.1158/2326-6066.22536622
Autor:
Willemijn A. Hobo, Erik H.J.G. Aarntzen, Harry Dolstra, Otto C. Boerman, Johan Bussink, Daniel Olive, Jeannette Cany, Soley Thordardottir, Gerwin W. Sandker, Janneke D.M. Molkenboer-Kuenen, Peter J. Wierstra, Sandra Heskamp
Supplemental Figure 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a95a629d837cf7f3d5f7d0adb0a391e
https://doi.org/10.1158/2326-6066.22536628
https://doi.org/10.1158/2326-6066.22536628
Autor:
Willemijn A. Hobo, Erik H.J.G. Aarntzen, Harry Dolstra, Otto C. Boerman, Johan Bussink, Daniel Olive, Jeannette Cany, Soley Thordardottir, Gerwin W. Sandker, Janneke D.M. Molkenboer-Kuenen, Peter J. Wierstra, Sandra Heskamp
Supplemental Figure 2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20b70b592ff8e0f3005183e9854b087a
https://doi.org/10.1158/2326-6066.22536625.v1
https://doi.org/10.1158/2326-6066.22536625.v1
Autor:
Willemijn A. Hobo, Erik H.J.G. Aarntzen, Harry Dolstra, Otto C. Boerman, Johan Bussink, Daniel Olive, Jeannette Cany, Soley Thordardottir, Gerwin W. Sandker, Janneke D.M. Molkenboer-Kuenen, Peter J. Wierstra, Sandra Heskamp
Supplemental Table 2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0236df3bc71f33d661c2cd6e36552898
https://doi.org/10.1158/2326-6066.22536613
https://doi.org/10.1158/2326-6066.22536613
Autor:
Willemijn A. Hobo, Erik H.J.G. Aarntzen, Harry Dolstra, Otto C. Boerman, Johan Bussink, Daniel Olive, Jeannette Cany, Soley Thordardottir, Gerwin W. Sandker, Janneke D.M. Molkenboer-Kuenen, Peter J. Wierstra, Sandra Heskamp
Supplemental Table 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a5248cad04ccd502a8ed6e467a97b6f
https://doi.org/10.1158/2326-6066.22536619
https://doi.org/10.1158/2326-6066.22536619
Autor:
Gerwin Sandker, René Raavé, Sandra Heskamp, Erik H.J.G. Aarntzen, Martin Gotthardt, Peter J. Wierstra, Johan Bussink, Gosse J. Adema
Publikováno v:
EJNMMI radiopharmacy and chemistry, 4, 1, pp. 29
EJNMMI Radiopharmacy and Chemistry
EJNMMI radiopharmacy and chemistry, 4, 29
EJNMMI Radiopharmacy and Chemistry, Vol 4, Iss 1, Pp 1-20 (2019)
EJNMMI Radiopharmacy and Chemistry
EJNMMI radiopharmacy and chemistry, 4, 29
EJNMMI Radiopharmacy and Chemistry, Vol 4, Iss 1, Pp 1-20 (2019)
Abstract Immunotherapy with checkpoint inhibitors demonstrates impressive improvements in the treatment of several types of cancer. Unfortunately, not all patients respond to therapy while severe immune-related adverse effects are prevalent. Currentl